KRAS and neoplasm: Although the effect of acetylation at residues Lys104 and Lys147 on regulating KRAS oncogenicity is inconsistent, it is unequivocally demonstrated that inhibition or knockdown of deacetylases such as SIRT1/2 and HDAC6 reduces the mutated KRAS-mediated tumor progression.